Scipher Medicine vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Scipher Medicine uses AI and network medicine to match autoimmune patients to effective therapies; PrismRA is the first molecular test approved to predict TNF inhibitor response in RA; $110M raised.
About
Scipher Medicine is a precision immunology company headquartered in Waltham, Massachusetts, applying AI and network biology to solve one of medicine's most persistent problems: predicting which therapy a patient with an autoimmune disease will actually respond to. The company's core platform integrates protein-protein interaction mapping, RNA sequencing data from the largest non-oncology clinico-transcriptomic biobank, and machine learning to identify molecular signatures that distinguish patients likely to respond from those likely to fail a given therapy.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.